GuardWire emboli protection device is associated with improved myocardial perfusion grade in saphenous vein graft intervention

American Heart Journal

Volumn 148, Issue 6, 2004, Pages 1003-1006

  Exaire, Jose E ^a   Brener, Sorin J ^a   Ellis, Stephen G ^a   Yadav, Jay S ^a   Bhatt, Deepak L ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DEVICE; EMBOLISM; EMBOLISM PREVENTION; FEMALE; HEART MUSCLE PERFUSION; HEART PROTECTION; HUMAN; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; SAPHENOUS VEIN GRAFT;

AGED; ANGINA, UNSTABLE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ARTERY BYPASS; CORONARY CIRCULATION; CORONARY DISEASE; EMBOLISM; FEMALE; GRAFT OCCLUSION, VASCULAR; HUMANS; MALE; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; RISK FACTORS; SAPHENOUS VEIN; STROKE VOLUME;

EID: 10644221873     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2004.06.015     Document Type: Article

References (20)

1. Heusch G., Schulz R., Baumgart D., et al. Coronary microembolization. Prog Cardiovasc Dis. 44:2001;217-230
2. Topol E.J., Yadav J.S. Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation. 101:2000;570-580
3. Stone G.W., Rogers C., Ramee S., et al. Distal filter protection during saphenous vein graft stenting technical and clinical correlates of efficacy. J Am Coll Cardiol. 40:2002;1882-1888
4. Stone G.W., Rogers C., Hermiller J., et al. Randomized comparison of distal protection with a filter-based catheter and a balloon occlusion and aspiration system during percutaneous intervention of diseased saphenous vein aorto-coronary bypass grafts. Circulation. 108:2003;548-553
5. Baim D.S., Wahr D., George B., et al. Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation. 105:2002;1285-1290
6. Michaels A.D., Appleby M., Otten M.H., et al. Pretreatment with intragraft verapamil prior to percutaneous coronary intervention of saphenous vein graft lesions results of the randomized, controlled Vasodilator Prevention on No-reflow (VAPOR) trial. J Invasive Cardiol. 14:2002;299-302
7. Gibson C.M., Cannon C.P., Murphy S.A., et al. Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction. Circulation. 105:2002;1909-1913
8. Gibson C.M., Cannon C.P., Murphy S.A., et al. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation. 101:2000;125-130
9. Rubin D.B. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 127:1997;757-763
10. Kearney M., Pieczek A., Haley L., et al. Histopathology of in-stent restenosis in patients with peripheral artery disease. Circulation. 95:1997;1998-2002
11. Dangas G., Mehran R., Lansky A.J., et al. Acute and long-term results of treatment of diffuse in-stent restenosis in aortocoronary saphenous vein grafts. Am J Cardiol. 86:2000;777-779., A6
12. Roffi M., Mukherjee D., Chew D.P., et al. Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts a pooled analysis of five randomized clinical trials. Circulation. 106:2002;3063-3067
13. Bhatt D.L., Topol E.J. Percutaneous coronary intervention for patients with prior bypass surgery therapy in evolution. Am J Med. 108:2000;176-177
14. Sdringola S., Assali A.R., Ghani M., et al. Risk assessment of slow or no-reflow phenomenon in aortocoronary vein graft percutaneous intervention. Catheter Cardiovasc Interv. 54:2001;318-324
15. Sdringola S., Assali A., Ghani M., et al. Adenosine use during aortocoronary vein graft interventions reverses but does not prevent the slow-no reflow phenomenon. Catheter Cardiovasc Interv. 51:2000;394-399
16. Ellis S.G., Chew D., Chan A., et al. Death following creatine kinase-MB elevation after coronary intervention identification of an early risk period: importance of creatine kinase-MB level, completeness of revascularization, ventricular function, and probable benefit of statin therapy. Circulation. 106:2002;1205-1210
17. Kini A., Marmur J.D., Kini S., et al. Creatine kinase-MB elevation after coronary intervention correlates with diffuse atherosclerosis, and low-to-medium level elevation has a benign clinical course implications for early discharge after coronary intervention. J Am Coll Cardiol. 34:1999;663-671
18. Oh J.K., Shub C., Ilstrup D.M., et al. Creatine kinase release after successful percutaneous transluminal coronary angioplasty. Am Heart J. 109:1985;1225-1231
19. Abdelmeguid A.E., Ellis S.G., Sapp S.K., et al. Defining the appropriate threshold of creatine kinase elevation after percutaneous coronary interventions. Am Heart J. 131:1996;1097-1105
20. Dillon M.C., Calbreath D.F., Dixon A.M., et al. Diagnostic problem in acute myocardial infarction CK-MB in the absence of abnormally elevated total creatine kinase levels. Arch Intern Med. 142:1982;33-38